Interleukin 1 receptor antagonist mediates the beneficial effects of systemic interferon beta in mice: implications for rheumatoid arthritis.

@article{Corr2011Interleukin1R,
  title={Interleukin 1 receptor antagonist mediates the beneficial effects of systemic interferon beta in mice: implications for rheumatoid arthritis.},
  author={Maripat Corr and David L. Boyle and Lisa M Ronacher and Brian R Lew and Lisa GM van Baarsen and Paul Peter Tak and Gary S. Firestein},
  journal={Annals of the rheumatic diseases},
  year={2011},
  volume={70 5},
  pages={858-63}
}
OBJECTIVES Interferon beta (IFNβ) therapy is effective in multiple sclerosis and murine models of arthritis. Surprisingly, systemic IFNβ treatment induces only minimal improvement in rheumatoid arthritis (RA). To explain this paradox, the authors evaluated the mechanism of IFNβ benefit in passive K/BxN arthritis and the effect of IFNβ treatment on RA synovium. METHODS Interleukin 10 (IL-10) null, IL-1 receptor antagonist (IL-1Ra) null, IL-1Ra transgenic and wild-type mice were administered K… CONTINUE READING